A. Sharma, M. Soni, S. Kumar, G.D. Gupta. Solubility enhancement—eminent role in poorly soluble drugs. Research Journal of Pharmacy and Technology 2 (2009) 220-224.‏ https://rjptonline.org/AbstractView.aspx?PID=2009-2-2-46

J. Hodgson. ADMET—turning chemicals into drugs. Nature Biotechnology 19 (2001) 722-726. https://doi.org/10.1038/90761‏

K.T. Savjani, A.K. Gajjar, J.K. Savjani. Drug Solubility: Importance and Enhancement Techniques. International Scholary Research Notices 2012 (2012) 1–10. https://doi.org/10.5402/2012/195727

C. Lipiniski, C.J Lipinski, C. Lipinski, C.A. Lipinski, C. Lipinski, C.A. Lipinski, Lipinski, C.A. Lipinski. Poor aqueous solubility - an industry wide problem in drug delivery. American Pharmaceutical Review 5 (2002) 82-85. https://www.scienceopen.com/document?vid=dbc999fb-0f66-463c-8166-d6576f8778d5

Z. Guo, C. Boyce, T. Rhodes, L. Liu, G.M. Salituro, K.J. Lee, A. Bak, D.H. Leung. A novel method for preparing stabilized amorphous solid dispersion drug formulations using acoustic fusion. International Journal of Pharmaceutics 592 (2021) 120026. https://doi.org/10.1016/j.ijpharm.2020.120026

V.R. Vemula, V. Lagishetty, S. Lingala. Solubility enhancement techniques. International Journal of Pharmaceutical Sciences Review and Research 5 (2010) 41-51.‏ https://globalresearchonline.net/journalcontents/volume5issue1/article-007.pdf

D.J. Pinto, M.J. Orwat, S. Koch, K.A. Rossi, R.S. Alexander, A. Smallwood, P.C. Wong, A.R. Rendina, J.M. Luettgen, R.M. Knabb, K. He, B. Xin, R.R. Wexler, P.Y.S. Lam. Discovery of 1-(4-methoxy¬phenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl) phenyl)-4, 5, 6, 7-tetrahydro-1 H-pyrazolo [3, 4-c] pyridine-3-carboxamide (Apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bio¬available inhibitor of blood coagulation factor Xa. Journal of Medicinal Chemistry 50 (2007) 5339-5356.‏ https://doi.org/10.1021/jm070245n

E.D. Deeks. Apixaban. Drugs 72 (2012) 1271-1291.‏ https://doi.org/10.2165/11209020-000000000-00000

Y. Falck-Ytter, C.W. Francis, N.A. Johanson, C. Curley, O.E. Dahl, S. Schulman, T.L. Ortel, S.G. Pauker, C.W.C. Jr. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141 (2012) e278S-e325S.‏ https://doi.org/10.1378/chest.11-2404

P.C. Wong, D.J. Pinto, D. Zhang. D. Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. Journal of Thrombosis and Thrombolysis 31 (2011) 478-492. https://doi.org/10.1007/s11239-011-0551-3

H. Li, A. Farajtabar, Y. Xie, Z. Li, H. Zhao. Apixaban (I) in several aqueous co-solvent mixtures: Solubility, solvent effect and preferential solvation. The Journal of Chemical Thermodynamics 150 (2020) 106200. https://doi.org/10.1016/j.jct.2020.106200

W. Byon, S. Garonzik, R.A. Boyd, C.E. Frost. Apixaban: a clinical pharmacokinetic and pharmacodynamic review. Clinical Pharmacokinetics 58 (2019) 1265-1279.‏ https://doi.org/10.1007/s40262-019-00775-z

D. Zhang, K. He, J.J. Herbst, J. Kolb, W. Shou, L. Wang, P.V. Balimane, Y.H. Han, J. Gan, C.E. Frost, W.G. Humphreys. Characterization of efflux transporters involved in distribution and disposition of apixaban. Drug Metabolism and Disposition 41 (2013) 827-835. https://doi.org/10.1124/dmd.112.050260

A. Jaber, I. Al-Ani, M. Hailat, E. Daoud, A. Abu-Rumman, Z. Zakaraya, B.J. Majeed, O. Al Meanazel, W.A. Dayyih. Esomeprazole and apixaban pharmacokinetic interactions in healthy rats. Heliyon 8 (2022) e11015. https://doi.org/10.1016/j.heliyon.2022.e11015

C. Ward, G. Conner, G. Donnan, A. Gallus S. McRae. Practical management of patients on apixaban: a consensus guide. Thrombosis Journal 11 (2013) 1-8. https://doi.org/10.1186/1477-9560-11-27

L. Wang, N. Raghavan, K. He, J.M. Luettgen, W.G. Humphreys, R.M. Knabb, D.J. Pinto, D. Zhang. Sulfation of o-demethyl apixaban: enzyme identification and species comparison. Drug Metabolism and Disposition 37 (2009) 802-808.‏ https://doi.org/10.1124/dmd.108.025593

M.E. Davis, M.E. Brewster. Cyclodextrin-based pharmaceutics: past, present and future. Nature Reviews Drug Discovery 3 (2004) 1023-1035.‏ https://doi.org/10.1038/nrd1576

M.M. Doile, K.A. Fortunato, I.C. Schmücker, S.K. Schucko, M.A.S. Silva, P.O. Rodrigues. Physicochemical properties and dissolution studies of dexamethasone acetate-β-Cyclodextrin inclusion complexes produced by different methods. AAPS PharmSciTech 9 (2008) 314-322. https://doi.org/10.1208/s12249-008-9042-z

ChemSpider database. http://www.chemspider.com/ (Accessed date: 01/08/2023).

Gaussian 09, Revision D.01, M.J. Frisch, G.W. Trucks, H.B. Schlegel, G.E. Scuseria, M.A. Robb, J.R. Cheeseman, G. Scalmani, V. Barone, B. Mennucci, G.A. Petersson, H. Nakatsuji, M. Caricato, X. Li, H.P. Hratchian, A.F. Izmaylov, J. Bloino, G. Zheng, J.L. Sonnenberg, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, J.A. Montgomery, J.E. Jr., Peralta, F. Ogliaro, M. Bearpark, J.J. Heyd, E. Brothers, K.N. Kudin, V.N. Staroverov, R. Kobayashi, J. Normand, K. Raghavachari, A. Rendell, J.C. Burant, S.S. Iyengar, J. Tomasi, M. Cossi, N. Rega, J.M. Millam, M. Klene, J.E. Knox, J.B. Cross, V. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R.E. Stratmann, O. Yazyev, A.J. Austin, R. Cammi, C. Pomelli, J.W. Ochterski, R.L. Martin, K. Morokuma, V.G. Zakrzewski, G.A. Voth, P. Salvador, J.J. Dannenberg, S. Dapprich, A.D. Daniels, Ö.Farkas, J.B. Foresman, J.V. Ortiz, J. Cioslowski, D.J. and Fox. Gaussian, Inc., Wallingford CT, 2009. https://www.scienceopen.com/document?vid=839f33cc-9114-4a55-8f1a-3f1520324ef5

Apixaban in: https://www.rxlist.com/eliquis-drug.htm (Accessed date: 20/04/2023).

Y. Chen, L. Li, J. Yao, Y.Y. Ma, J.M. Chen, T.B. Lu. Improving the solubility and bioavailability of apixaban via apixaban–oxalic acid cocrystal. Crystal Growth and Design 16 (2016) 2923-2930.‏ https://doi.org/10.1021/acs.cgd.6b00266

S. Sip, A. Gościniak, P. Szulc, J. Walkowiak, J. Cielecka-Piontek, J. Assisted Extraction with cyclodextrins as a way of improving the Antidiabetic activity of actinidia leaves. Pharmaceutics 14 (2022) 2473. https://doi.org/10.3390/pharmaceutics14112473